Evidence map›Paper›PMID 42151323›Full record

ArticleScientific reports2026

Post-Chornobyl thyroid papillary carcinomas display distinct past

Catherine Ory, Charline Jouannet, Leonardo Panunzi, Asma Nouira, Marc Benderitter, Bernard Le Guen, Martin Schlumberger, Florent de Vathaire, Jean-François Deleuze, Tetiana I Bogdanova and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Catherine OryCEA, DRCM, Université Paris-Saclay, 92265, Fontenay-aux-Roses, France.
Charline JouannetRadiobiology and Regenerative Medicine Research Service, Autorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/Radiobiology Laboratory for Accidental Exposure, IRSN PSE-SANTE/SERAMED/LRAcc, 31 av de la Division Leclerc, 92260, Fontenay-aux-Roses, France.
Leonardo PanunziDepartment of Bioinformatics, Lymphoma Study Association Clinical Research, Pierre Bénite, France.
Asma NouiraRadiobiology and Regenerative Medicine Research Service, Autorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/Radiobiology Laboratory for Accidental Exposure, IRSN PSE-SANTE/SERAMED/LRAcc, 31 av de la Division Leclerc, 92260, Fontenay-aux-Roses, France.
Marc BenderitterAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE, F-92260, Fontenay-aux-Roses, France.
Bernard Le GuenEDF, DPN, Saint-Denis, France.
Martin SchlumbergerDepartment of Endocrine Oncology, Gustave Roussy and University Paris-Saclay, Villejuif, France.
Florent de VathaireRadiation Epidemiology Team, Unit 1018 CESP INSERM and University Paris-Saclay, F-94805, Villejuif, France.
Jean-François DeleuzeCentre National de Recherche en Génomique Humaine (CNRGH), Institut François Jacob, CEA, Université Paris-Saclay, 91000, Évry-Courcouronnes, France.
Tetiana I BogdanovaSI "Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine", 69 Vyshgorodska Street, Kyiv, 04114, Ukraine.
Mykola TronkoSI "Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine", 69 Vyshgorodska Street, Kyiv, 04114, Ukraine.
Victor V PushkarevSI "Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine", 69 Vyshgorodska Street, Kyiv, 04114, Ukraine.
Sergii MasiukState Institution "National Research Center for Radiation Medicine, Hematology and Oncology of the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine.
Maâmar SouidiRadiobiology and Regenerative Medicine Research Service, Autorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/Radiobiology Laboratory for Accidental Exposure, IRSN PSE-SANTE/SERAMED/LRAcc, 31 av de la Division Leclerc, 92260, Fontenay-aux-Roses, France.
Mohamed Amine BenadjaoudRadiobiology and Regenerative Medicine Research Service, Autorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/Radiobiology Laboratory for Accidental Exposure, IRSN PSE-SANTE/SERAMED/LRAcc, 31 av de la Division Leclerc, 92260, Fontenay-aux-Roses, France. mohamedamine.benadjaoud@asnr.fr.

Funding

The Chernobyl Tissue Bank - Coordinating CenterU24CA082102 · NCI · UNIVERSITY OF WALES, SWANSEA · PI THOMAS, GERALDINE ANNE · 2000 to 2021
$4.6M
NCI NIH HHS U24 CA082102
6 · The paper itself

Abstract

Most previous studies aimed to establish etiological signatures of thyroid tumors compared sporadic papillary thyroid carcinomas (sPTC) and PTC that develop in individuals exposed to ionizing radiation during childhood. However, such approaches may lead to a biased signature combining exposure markers independent of the carcinogenic process and markers of radiation-induced carcinogenesis. We analyzed the miRNome (Affymetrix) and transcriptome (RNA sequencing) of a series of normal thyroid tissues and PTC from Ukrainian individuals contaminated with iodine-131 released by the Chornobyl Nuclear Power Plant in 1986 at high (> 0.5 Gy; N = 9) or low (< 50 mGy; N = 12) thyroid radiation doses, and from unexposed Ukrainian individuals (N = 28). First, the six sample groups were analyzed jointly using partial least squares discriminant analysis (sPLS-DA) to assess whether normal tissues and PTC shared common multi-omic signatures associated with exposure history, independent of carcinogenesis. Next, we applied a multiblock sPLS-DA (DIABLO) to isolate markers associated with exposure in the three normal tissue groups. Then, using the remaining miR and genes from the datasets not associated with exposure, we searched for a multi-omics signature associated with a difference in the carcinogenic process. sPLS-DA analysis of the six sample groups showed that normal tissues and PTC from exposed individuals shared a common multi-omics signature (58 miR/snoRNA, 50 genes) compared to unexposed samples. Our DIABLO analysis identified 44 miR/snoRNA and 45 genes exposure signatures distinguishing exposed from unexposed normal tissues. These signatures, when applied to PTC groups, supported that PTC developed after radiation exposure exibited exposure markers independent of any carcinogenic process. In addition to this exposure signature, we identified 39 miR/snoRNA and 64 genes signatures that identified the PTC developed after radiation exposure which deviated significantly from the sPTC profile. Normal tissues and PTC from exposed individuals exhibit a common molecular long-term memory of exposure history. Furthermore, PTC developed after radiation exposure display dose-dependent molecular specificities compared to sPTC. As PTC associated with low doses are mainly subclinical sPTC revealed by screening in the post-Chornobyl population, the proposed multi-omic signature could be attributable to sPTC developed in an exposed thyroid gland.

Indexed as

CarcinogenesisChernobyl Nuclear AccidentIodine RadioisotopesNeoplasms, Radiation-InducedThyroid Cancer, PapillaryThyroid GlandThyroid NeoplasmsAdultFemaleGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedRadiation ExposureTranscriptomeIodine-131Iodine RadioisotopesMicroRNAsChornobylLow radiation dosemiRNome, transcriptomeMolecular signatureNormal tissueRadiation-induced thyroid tumor

Identifiers

PMID42151323
PMCPMC13381904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.